A growing understanding of the molecular interactions between immune effector cells and target tumor cells, coupled with refined gene therapy approaches, are giving rise to novel cancer immunotherapeutics with remarkable efficacy in the clinic against both solid and liquid tumors. To date, the most successful immunotherapies are those targeting blood-borne tumors. In recent years, CAR (Chimeric Antigen Receptor)-T Cell therapy has been one of the most prominent and breakthrough in cancer immunotherapy for relapsed and refractory hematopoietic malignancies. In response to this, ACEA sought to adapt the xCELLigence Real-Time Cell Analysis (RTCA®) system potency assay for in vitro assessment of immunotherapies targeting tumor cell lines originating from liquid tumors. Learn how this was achieved as well as the principles and protocols used.
Read Application Note